AxoGen (AXGN) Tops Q2 EPS by 9c; Reaffirms FY22 Guidance

AxoGen (NASDAQ: AXGN) reported Q2 EPS of ($0.06), $0.09 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $34.5 million versus the consensus estimate of $33.82 million.

GUIDANCE:

AxoGen sees FY2022 revenue of $135-142 million, versus the consensus of $139.3 million.

For earnings history and earnings-related data on AxoGen (AXGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery